Falahat, Rana http://orcid.org/0000-0001-7489-3807
Berglund, Anders http://orcid.org/0000-0002-0393-3530
Perez-Villarroel, Patricio
Putney, Ryan M.
Hamaidi, Imene
Kim, Sungjune http://orcid.org/0000-0001-7100-1252
Pilon-Thomas, Shari
Barber, Glen N.
Mulé, James J. http://orcid.org/0000-0001-7354-0516
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA076292, P50 CA168536)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 2 August 2022
Accepted: 6 March 2023
First Online: 22 March 2023
Competing interests
: J.J.M. is Associate Center Director at Moffitt Cancer Center, has ownership interest in Aleta Biotherapeutics, CG Oncology, Turnstone Biologics, Ankyra Therapeutics, and AffyImmune Therapeutics, and is a paid consultant/paid advisory board member for ONCoPEP, CG Oncology, Mersana Therapeutics, Turnstone Biologics, Vault Pharma, Ankyra Therapeutics, AffyImmune Therapeutics, UbiVac, Vycellix, and Aleta Biotherapeutics.